PRGO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.10B

-3.33%

0.784

-15.72%

1.06B

+1.56%

0.650

+8.33%

1.04B

-1.9%

0.610

+7.02%

Estimates Revision

The market is revising Downward the revenue expectations for Perrigo Company plc (PRGO) for FY2025, with the revenue forecasts being adjusted by -2.96% over the past three months. During the same period, the stock price has changed by -31.59%.

Revenue Estimates for FY2025

Revise Downward

-2.96%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.67%

In Past 3 Month

Stock Price

Go Down

-31.59%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

23.00

Averages

27.50

High

32.00

Current: 0.000

Low

23.00

Averages

27.50

High

32.00

JPMorgan

Neutral

downgrade

$20 -> $18

2025-12-15

Reason

JPMorgan

Price Target

$20 -> $18

2025-12-15

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Perrigo to $18 from $20 and keeps a Neutral rating on the shares. The firm updated the company's model.

Canaccord

Buy

downgrade

$40 -> $20

2025-11-06

Reason

Canaccord

Price Target

$40 -> $20

2025-11-06

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Perrigo to $20 from $40 and keeps a Buy rating on the shares. The firm noted Q3 was a beat but sales were weak in light of OTC trends and lower nutrition sales due to velocities below expectations and lapping a period where infant formula benefited from selling into retailers due to the port strike last year.

JPMorgan

Overweight -> Neutral

downgrade

$32 -> $20

2025-11-06

Reason

JPMorgan

Price Target

$32 -> $20

2025-11-06

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Perrigo to Neutral from Overweight with a price target of $20, down from $32, post the Q3 report. The firm sees increased uncertainty for the business in the near term and over the next 12 months. The recovery in Perrigo's infant formula business is slower than expected amid competitive pressure and its over-the-counter market trends are uncertain, the analyst tells investors in a research note. JPMorgan prefers to revisit shares when it gets more clarity on these dynamics.

Jefferies

Keith Devas

Hold

downgrade

$27 -> $23

2025-10-27

Reason

Jefferies

Keith Devas

Price Target

$27 -> $23

2025-10-27

downgrade

Hold

Reason

Jefferies analyst Keith Devas lowered the firm's price target on Perrigo to $23 from $27 and keeps a Hold rating on the shares. Macro headwinds continue to be felt more acutely in consumer health than other pockets of staples, says the analyst, who lowered targets and estimates across the firm's consumer health coverage into Q3 earnings reports from the group.

Canaccord

Susan Anderson

Buy

downgrade

$42 -> $40

2025-08-07

Reason

Canaccord

Susan Anderson

Price Target

$42 -> $40

2025-08-07

downgrade

Buy

Reason

Canaccord analyst Susan Anderson lowered the firm's price target on Perrigo to $40 from $42 and keeps a Buy rating on the shares. The firm updated its model following Q2 results where sales were down but management reiterated both top and bottom-line expectations which are achievable given the company's limited tariff exposure, opportunity to benefit from trade down, new contract wins in PL OTC, and continued strong European business.

Valuation Metrics

The current forward P/E ratio for Perrigo Company PLC (PRGO.N) is 4.80, compared to its 5-year average forward P/E of 12.47. For a more detailed relative valuation and DCF analysis to assess Perrigo Company PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.47

Current PE

4.80

Overvalued PE

16.66

Undervalued PE

8.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.88

Current EV/EBITDA

7.35

Overvalued EV/EBITDA

12.89

Undervalued EV/EBITDA

8.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.00

Current PS

0.45

Overvalued PS

1.25

Undervalued PS

0.75

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 107.21% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 107.21% over the last month.

Sold

Bought

PRGO News & Events

Events Timeline

No data

News

7.0

14:50 PMPRnewswire

Perrigo Faces Class Action for Misleading Statements; Deadline January 16

7.0

01-07Globenewswire

Perrigo Company Securities Class Action Initiated, Compensation Deadline January 16

7.0

01-07PRnewswire

Perrigo Faces Securities Fraud Class Action Over Infant Formula Business

People Also Watch

Frequently Asked Questions

What is Perrigo Company PLC (PRGO) stock price today?

The current price of PRGO is 14.81 USD — it has increased 1.51 % in the last trading day.

What is Perrigo Company PLC (PRGO)'s business?

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

What is the price predicton of PRGO Stock?

What is Perrigo Company PLC (PRGO)'s revenue for the last quarter?

Perrigo Company PLC revenue for the last quarter amounts to 1.04B USD, decreased -4.06 % YoY.

What is Perrigo Company PLC (PRGO)'s earnings per share (EPS) for the last quarter?

Perrigo Company PLC. EPS for the last quarter amounts to 0.05 USD, decreased -133.33 % YoY.

What changes have occurred in the market's expectations for Perrigo Company PLC (PRGO)'s fundamentals?

How many employees does Perrigo Company PLC (PRGO). have?

Perrigo Company PLC (PRGO) has 8379 emplpoyees as of January 08 2026.

What is Perrigo Company PLC (PRGO) market cap?

Today PRGO has the market capitalization of 2.01B USD.